Multivariate analysis for patients with multiple myeloma and non-Hodgkin lymphoma: overall survival and progression-free survival rates
| Prognostic factors . | Multiple myeloma . | Non-Hodgkin lymphoma . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR . | Overall survival, 95% CI . | P . | RR . | Progression-free survival, 95% CI . | P . | RR . | Overall survival, 95% CI . | P . | RR . | Progression-free survival, 95% CI . | P . | |
| ALC ≥ 500 cells/μL vs < 500 cells/μL | .176 | .075 -.414 | .0001 | .275 | .13 -.98 | .0006 | .08 | .04 -.17 | .0001 | .09 | .04 -.19 | .0001 |
| Circulating plasma cells | .27 | .11 -.65 | .0035 | .33 | .15 -.75 | .008 | ||||||
| PCLI ≥ 1% vs < 1% | .3 | .11 -.79 | .014 | |||||||||
| Platelet level > 20 × 109/L vs < 20 × 109/L | .18 | .06 -.5 | .001 | |||||||||
| Relapse on therapy vs plateau/response | 8.45 | 1.64 -43.58 | .011 | |||||||||
| Prognostic factors . | Multiple myeloma . | Non-Hodgkin lymphoma . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR . | Overall survival, 95% CI . | P . | RR . | Progression-free survival, 95% CI . | P . | RR . | Overall survival, 95% CI . | P . | RR . | Progression-free survival, 95% CI . | P . | |
| ALC ≥ 500 cells/μL vs < 500 cells/μL | .176 | .075 -.414 | .0001 | .275 | .13 -.98 | .0006 | .08 | .04 -.17 | .0001 | .09 | .04 -.19 | .0001 |
| Circulating plasma cells | .27 | .11 -.65 | .0035 | .33 | .15 -.75 | .008 | ||||||
| PCLI ≥ 1% vs < 1% | .3 | .11 -.79 | .014 | |||||||||
| Platelet level > 20 × 109/L vs < 20 × 109/L | .18 | .06 -.5 | .001 | |||||||||
| Relapse on therapy vs plateau/response | 8.45 | 1.64 -43.58 | .011 | |||||||||
Likelihood ratio, P < .0001.
RR indicates relative risk; for other abbreviations, see Tables 1 and3.